Demystifying DEA’s Role & Implementing a Zero Risk Program
The Waivered Prescriber Support Initiative (WPSI) presents a monthly webinar series targeting different topics of interest and concern facing clinicians who prescribe buprenorphine for opioid use disorder (OUD). The first one-hour webinar in the series will be held on Monday, December 16, 2019, and the topic will be Demystifying DEA’s Role & Implementing a Zero Risk Program presented by retired DEA Special Agent, Dennis Wichern.
Monday, December 16th from 12 - 1pm – Demystifying DEA’s Role & Implementing a Zero Risk Program
Featured speaker: Dennis Wichern, MSc, Retired DEA Special Agent
This one-hour web training will provide an overview of the authority of the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), and Substance Abuse and Mental Health Services Administration (SAMHSA) as it relates to regulating the use of medications in the provision of treatment for opioid use disorders (OUD), along with a review of national studies, risk mitigation strategies, case studies, emerging issues, commonly asked questions, and strategies for preventing a DEA audit. The goal of the training session is to alleviate provider concerns relative to operating a MAT medical practice.
1. Describe DEA’s limited role in the practice of medicine and MAT
2. Recognize at least three important strategies in operating a zero risk MAT medical practice
3. List at least two of the latest drugs trends that impact MAT providers nationwide
4. Discuss at least two recent MAT case studies
Note: once you register, you will be able to attend any of our future sessions. You can cancel your registration at any time.